| Objective:To evaluate the effect of neoadjuvant chemotherapy in the treatment of primary resectable colorectal liver metastases(CRLM)with Meta-analysis method.Methods:A literature search was performed in Pub Med,Cochrane Library,Embase,CNKI,Wanfang databases,the retrieval time was from January 2006 to January 2021,the assessment data about patients receiving neoadjuvant chemotherapy were collected and processed using Rev Man 5.4 software for Meta-analysis.Results:A total of 6 644 patients from 12 relevant literatures were enrolled in this study,including 3 348 patients in the neoadjuvant chemotherapy group and 3 296 patients in the simple operation group.The 3-year disease-free survival rate of the simple operation group was better than that of the neoadjuvant chemotherapy group(OR=0.57,95% CI:0.48-0.68,P<0.001),the operative time was shorter(WMD=13,95% CI: 12.78-13.22,P<0.001).There were no significant differences in complication rate,intrahepatic recurrence rate,length of hospital stay and 5-year overall survival rate between the two groups.Conclusion:Neoadjuvant chemotherapy is safe for patients with initially resectable CRLM,but the long-term benefit is not obvious.Neoadjuvant chemotherapy may prolong the survival time of patients with high recurrence risk. |
PDF Full Text Request